ID: ALA4165270

Max Phase: Preclinical

Molecular Formula: C16H30N2O4

Molecular Weight: 314.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)=CCCC(C)CC(=O)NC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C16H30N2O4/c1-10(2)5-4-6-11(3)7-14(20)18-8-12-15(21)16(22)13(19)9-17-12/h5,11-13,15-17,19,21-22H,4,6-9H2,1-3H3,(H,18,20)/t11?,12-,13+,15+,16-/m1/s1

Standard InChI Key:  DVXMUIQYYZDABT-LSMPXOGUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 314.43

Molecular Weight (Monoisotopic): 314.2206

AlogP: -0.07

#Rotatable Bonds: 7

Polar Surface Area: 101.82

Molecular Species: NEUTRAL

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.92

CX Basic pKa: 7.85

CX LogP: -0.08

CX LogD: -0.66

Aromatic Rings: 0

Heavy Atoms: 22

QED Weighted: 0.42

Np Likeness Score: 1.52

References

1. Li HY, Lee JD, Chen CW, Sun YC, Cheng WC..  (2018)  Synthesis of (3S,4S,5S)-trihydroxylpiperidine derivatives as enzyme stabilizers to improve therapeutic enzyme activity in Fabry patient cell lines.,  144  [PMID:29289886] [10.1016/j.ejmech.2017.12.036]

Source

Source(1):

• Scientific Literature